+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 84 Actively Recruiting clinical trials

A

Actively Recruiting

Healthy Volunteer

Researchers are creating a registry to study people with early changes in the stomach lining that may lead to gastric cancer. This includes those with gastric atrophy, intestinal metaplasia, and dysplasia. The study also enrolls healthy individuals and people with gastric cancer to compare baseline characteristics and better understand risk factors for disease progression. Participants fall into three groups those with specific stomach lesions, healthy controls, and people with gastric cancer. The study collects information through questionnaires about clinical history, environmental exposures, lifestyle, and diet. This observational study does not involve any treatment but gathers health data to support future research. Participants will complete questionnaires and provide health information over a period that may last up to 10 years. The main goal is to build a detailed participant registry. Researchers will monitor and analyze the collected data to identify factors related to the progression of stomach lesions to cancer. Participation involves regular data collection but no active treatment, with safety and privacy monitored throughout the study.

Age: 18Years +All Genders
7 locations
C

Actively Recruiting

Researchers are studying the long-term quality of life in patients with lymphedema who choose to have surgery using vascularized lymph node transfer VLNT compared to those who opt for non-surgical management. The study aims to understand how these different choices impact patients well-being over time. Participants in this observational study are either those who have elected to undergo VLNT surgery or those considering or receiving non-surgical treatment for lymphedema. There is no active therapeutic intervention administered by the study during the follow-up period. The study uses quality of life assessments including ULL-27 for upper limb lymphedema, the Lymphedema Life Impact Scale version 2 LLISv2, and LYMQOL-Leg to evaluate participants. Throughout the study, participants will complete these quality of life questionnaires up to 40 months to track changes and outcomes. The study does not involve treatment delivery but focuses on monitoring and assessing patient-reported outcomes. The total duration of participation can extend up to 40 months, allowing for comprehensive long-term follow-up by the research team.

Age: 18Years - 80YearsAll Genders
3 locations
P

Actively Recruiting

Researchers are evaluating whether combining the biological agent 2141-V11 with various standard treatments can be an effective approach for treating prostate cancer. This study focuses on men with clinically localized or locoregional high-risk disease, as well as those with low-volume metastatic disease where removing the primary tumor combined with other treatments might eliminate all cancer cells. The treatment works by activating the immune system to target and kill cancer cells, with researchers monitoring for complete cancer response and minimal residual disease MRD, which is a small number of cancer cells that may remain after treatment. Participants will receive intratumoral injections of the anti-CD40 agonist antibody 2141-V11. For men with intermediate risk disease, the antibody is given before radical prostatectomy, while those with high-risk localized or low-volume metastatic disease will receive the antibody in combination with androgen deprivation therapy. The study is non-randomized and involves single-site injections of 2141-V11 as monotherapy or combined with standard therapies, depending on the disease stage. During the study, participants will undergo clinical assessments including prostate MRI scans and staging evaluations. Researchers will monitor participants over 24 months to measure the number who achieve complete response or have minimal residual disease. Safety and treatment effects will be closely observed through laboratory tests, physical exams, and documentation of any side effects. Participants adherence to birth control requirements and other safety measures will also be monitored throughout the study period.

Age: 18Years +MALEPhase 2
7 locations
E

Actively Recruiting

Researchers are evaluating the practicality of using a new imaging technique called 68Ga-FAPI PETMRI to see how well breast cancer responds to neoadjuvant chemotherapy. This study focuses on adults newly diagnosed with invasive breast cancer who have lymph node involvement and are planning to receive standard chemotherapy before surgery. The study is sponsored by Memorial Sloan Kettering Cancer Center and is designed as a phase 1 interventional trial. Participants will undergo three 68Ga-FAPI PETMRI scans during the study. These scans are performed to monitor the breast cancers response to chemotherapy. The study does not involve any comparison groups or masking. The imaging helps evaluate the extent of cancer and treatment effects before surgical removal. During the study, participants will be closely monitored to complete all three planned scans within up to one year. Researchers will assess the number of participants who can complete these scans. The study includes various assessments such as imaging procedures, performance status evaluations, and informed consent procedures. The total duration for participation depends on completing the scans and chemotherapy timeline.

Age: 18Years +All GendersPhase 1
8 locations
S

Actively Recruiting

This study is exploring whether it is practical to conduct a larger trial evaluating the Breast Reconstruction Decision Aid Tool RECONJOINT for people considering breast reconstruction surgery after mastectomy. It aims to assess the feasibility of using this decision aid to support patients in making informed choices about reconstruction. The study involves participants with breast cancer or genetic predisposition to breast cancer who are considering post-mastectomy reconstruction. Participants are assigned to either usual care or to receive RECONJOINT along with enhanced usual care. Surgeons are randomized to either provide enhanced usual care or the intervention using RECONJOINT in a parallel design. Those in the intervention arm receive the decision aid to help guide their breast reconstruction decisions before surgery. Participants will be involved from their initial reconstructive surgery consultation through surgery. Researchers will track how many patients join within 60 days after the consult and before surgery to determine feasibility. The study is sponsored by Memorial Sloan Kettering Cancer Center and includes monitoring participant accrual as a primary outcome. The total study period extends to early 2029.

Age: 18Years +All GendersPhase Not Applicable
9 locations
E

Actively Recruiting

Researchers are evaluating a new total-body PET scanner called the Biograph Vision Quadra for people with cancer. The goal is to determine if this scanner produces better PETCT images and provides more useful imaging information than standard PETCT scanners. This study is a quality improvement protocol focused on advanced imaging performance for patients with lung, head and neck, or prostate cancer. Participants will undergo one or two additional scans using the Biograph Vision Quadra scanner alongside their planned PETCT scans performed as part of standard care or other clinical trials. The study includes imaging with different radiotracers such as 68Ga-PSMA, 18F-FDG, or 18F-fluormisonidazole, with some participants returning for late imaging sessions 2 to 6 hours after radiotracer injection. During the study, participants will have PETCT imaging data collected to assess image quality over three years. Additional imaging techniques like breath-hold, dynamic, or delayed acquisitions may be used. Researchers will monitor image quality and pharmacokinetics of radiotracer uptake across disease sites. The total participation time depends on scheduled scans and follow-up imaging sessions.

Age: 18Years +All Genders
7 locations
I

Actively Recruiting

Researchers are evaluating whether a navigation program can help people with various types of cancer manage their immunotherapy treatment better than usual care. This study focuses on patients with kidney, bladder, breast, gastrointestinal, or lung cancer who are starting immune checkpoint inhibitor therapies. The trial aims to understand if this program improves treatment continuation and quality of life. Participants are randomly assigned to either the Immunotherapy CARE Program, where staff assist monthly with essential needs and side effects or symptom navigation, or to enhanced usual and customary care without this navigation support. The study compares these two groups to assess differences in managing treatment and support needs. During the study, participants will complete questionnaires to measure their quality of life and report symptoms. Researchers will monitor continuation of immune checkpoint inhibitor treatment over a 6-month period. The study includes regular contact to assess needs, side effects, and treatment adherence, with the total duration lasting up to six months from the start of therapy.

Age: 18Years +All GendersPhase Not Applicable
8 locations
P

Actively Recruiting

Researchers are evaluating different doses of abemaciclib combined with hormone therapy and radiation therapy in people diagnosed with metastatic hormone receptor-positive HR, HER2-negative breast cancer. This Phase I study aims to find the maximum tolerated dose of abemaciclib when given alongside radiation therapy to bone metastases, helping to identify the best dose for future treatments. Participants will receive abemaciclib orally every 12 hours starting on the day of radiation therapy simulation through the end of radiotherapy, which lasts up to 28 days. Radiation therapy is given as either 27 Gy in 3 daily fractions or 30 Gy in 5 daily fractions, all completed within 28 days. After determining the maximum tolerated dose, additional patients needing bone metastases palliation will be enrolled for further evaluation. During the study, participants will undergo regular assessments to monitor tolerability and side effects over a period of up to one year. Researchers will track the maximum tolerated dose of abemaciclib and evaluate patient recovery from prior treatments. Participants must have adequate organ function and be able to swallow oral medications. Safety monitoring and adherence to treatment schedules will be part of the study procedures throughout the trial duration.

Age: 18Years +All GendersPhase 1
7 locations
M

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a psychotherapy program designed to reduce anxiety in Latino older adults with cancer and their caregivers. The study aims to determine if this anxiety treatment is practical and effective for this group. The research is supported by Memorial Sloan Kettering Cancer Center and focuses on supportive care for cancer patients and their caregivers. The intervention, called Managing Anxiety from Cancer MAC, involves seven psychotherapy sessions lasting 45 to 60 minutes each. These sessions are conducted via videoconference or telephone by licensed social workers or advanced mental health trainees. All sessions are audio-recorded and structured around key components of cognitive behavioral therapy CBT. Participants include Latino older adults with cancer and their caregivers. The study monitors whether participants complete all study procedures over one year. Researchers collect information through session recordings and track adherence to the intervention. The study also includes assessments of language fluency and anxiety levels using the Hospital Anxiety and Depression Scale HADS. Participants may be evaluated for safety and ability to complete study activities throughout the trial.

Age: 40Years +All GendersPhase Not Applicable
7 locations
S

Actively Recruiting

Researchers are evaluating whether Stimulan Rapid Cure can reduce infections in people undergoing tissue expander placement during mastectomy for breast cancer or related preventive reasons. The study also examines if this antibiotic delivery affects the risk of seroma, a complication involving fluid buildup after surgery. This is a randomized, phase 4 clinical trial assessing the prevention of breast tissue expander-associated infections. Participants are assigned to one of two groups one receives tissue expanders with antibiotic beads containing vancomycin and gentamicin delivered through Stimulan Rapid Cure during surgery, and the other receives tissue expanders alone. The study compares infection and seroma rates within 90 days after surgery to evaluate the effectiveness of the antibiotic delivery device. During the trial, participants will undergo mastectomy with immediate breast reconstruction using prepectoral tissue expanders at Memorial Sloan Kettering Cancer Center. Researchers will monitor surgical site infections and seroma formation for 90 days postoperatively. The study involves regular follow-up to assess these outcomes and ensure participant safety throughout the trial period.

Age: 18Years +FEMALEPhase 4
7 locations

1-10 of 84

1